Compare Tata India Pharma & Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Risk | Very High | Very High |
Rating | 3.0 | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2.1 | 1.86 |
NAV | ₹28.89 | ₹37.51 |
Fund Started | 04 Dec 2015 | 25 Jun 2018 |
Fund Size | ₹1310.50 Cr | ₹6455.55 Cr |
Exit Load | Exit load of 0.25% if redeemed within 30 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
3.0
5.0
Min SIP Amount
₹100
₹100
Expense Ratio
2.1
1.86
NAV
₹28.89
₹37.51
Fund Started
04 Dec 2015
25 Jun 2018
Fund Size
₹1310.50 Cr
₹6455.55 Cr
Exit Load
Exit load of 0.25% if redeemed within 30 days.
Exit load of 1% if redeemed within 15 days.
1 Year | -3.96% | -1.54% |
3 Year | 20.52% | 25.69% |
5 Year | 13.76% | 16.06% |
1 Year
-3.96%
-1.54%
3 Year
20.52%
25.69%
5 Year
13.76%
16.06%
Equity | 98.68% | 97.87% |
Cash | 1.32% | 2.13% |
Equity
98.68%
97.87%
Cash
1.32%
2.13%
Top 10 Holdings |
|
|
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 7.88% |
Max Healthcare Institute Ltd. | 5.87% |
Abbott India Ltd. | 5.48% |
Divi's Laboratories Ltd. | 5.01% |
Healthcare Global Enterprises Ltd. | 4.84% |
Apollo Hospitals Enterprise Ltd. | 4.76% |
Cipla Ltd. | 4.14% |
Rainbow Children's Medicare Ltd. | 3.77% |
Ipca Laboratories Ltd. | 3.72% |
JB Chemicals & Pharmaceuticals Ltd. | 3.52% |
Sun Pharmaceutical Industries Ltd. | 12.05% |
Cipla Ltd. | 7.90% |
Dr. Reddy's Laboratories Ltd. | 7.82% |
Divi's Laboratories Ltd. | 7.10% |
Mankind Pharma Ltd. | 6.44% |
Lupin Ltd. | 5.78% |
Aurobindo Pharma Ltd. | 5.19% |
Alkem Laboratories Ltd. | 3.66% |
Cohance Lifesciences Ltd. | 3.01% |
Syngene International Ltd. | 2.98% |
Name | - | - |
Start Date | - | - |
Name
-
-
Start Date
-
-
Description | The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 04 Dec 2015 | 25 Jun 2018 |
Description
The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
04 Dec 2015
25 Jun 2018